Lake Street Maintains Buy on Kyntra Bio, Lowers Price Target to $8

Benzinga · 18h ago
Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.